Investigations for bleeding disorders are warranted when a patient presents with a personal and/or family history of bleeding, and/ or laboratory abnormalities that suggest an inherited or acquired bleeding disorder.
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HAYWARD

| ME THODS
In this review, we summarize our current strategy for investigating bleeding problems, highlighting important scientific evidence, and considerations including issues relevant to test interpretation.
| RE SULTS
A practical and rational strategy for investigating bleeding disorders should consider scientific evidence and insights from experience. The strategy needs to be practical, with consideration of: the clinical scenario and personal and family bleeding history (eg, nature, type, and severity of bleeding problems, and if they are longstanding or new); the pretest probability of a bleeding disorder (which is high for patients referred for bleeding disorder assessments, unlike preoperative patients); if the person's surgical/dental/traumatic bleeding typically begins on the day of the challenge (the most common scenario) or if it begins one or more days later (a less common scenario that suggests defects in coagulation, clot stabilization, or fibrinolysis); the range of potential causes, from common to rare; the possibility of true-positive, false-positive, false-negative or true-negative findings; the scope and type investigations that can be performed locally or at a referral center; and strategies to limit how many times blood will be drawn to complete the investigations.
We implemented a standardized approach for evaluating bleeding disorders many years ago that facilitated an evaluation of the sensitivity and specificity of individual tests and test panels for bleeding disorders.
1,2 Figure 1 summarizes our updated scheme for bleeding disorder investigations, including follow-up tests to consider after initial investigations. Both congenital and acquired bleeding disorder can be approached by this strategy. Table 1 summarizes important test considerations.
While streamlined testing is often helpful, there are situations that require an individualized approach. A good example is the diagnostic testing of a cord blood sample for a specific disorder that affects the newborn's parent or sib(s). Another example is prioritizing investigations when a child is too small to draw the volume of blood needed F I G U R E 1 Strategy used to guide bleeding disorder diagnosis. This figure (which revises our previous scheme, published in 2) summarizes the author's current recommendations for the initial investigations of a suspected bleeding disorder and the subsequent investigations that should be considered to confirm the diagnosis or to further evaluate the cause, based on initial test findings. TT, thrombin time; VWD, von Willebrand disease; VWF, von Willebrand factor for complete investigations. Rarer, autosomal recessive bleeding disorders deserve greater consideration when the patient is from a region with a high prevalence of rare disorders or a culture that accepts consanguinity. Acquired VW syndrome (AVWS) and acquired platelet function disorders are often suspected in patients with an underlying blood disorder (eg, a myeloproliferative or lymphoproliferative neoplasm, monoclonal gammopathy) or other conditions (eg, stenosis of the aortic valve). The elderly are at higher risk for autoantibodyinduced disorders, including acquired hemophilia, factor V deficiency, XIII deficiency, and AVWS from a monoclonal gammopathy.
TA B L E 1 Important technical and diagnostic considerations for bleeding disorder tests
Tests
Technical and diagnostic considerations
PT/INR Assesses factors II, V, VII, and X Does not detect most fibrinogen disorders Abnormalities need further investigation by specific factor assays (eg, to quantify factor VII if the APTT is normal) The test is prolonged in persons with Factor V-Short who have normal levels of factor V but increased plasma TFPI due to their altered factor V Current reagents can neutralize up to approximately 1 U/mL of heparin. If a bleeding disorder is suspected, factor assays should be performed to rule out a factor deficiency, regardless of any 1:1 mixing study findings PTT Assesses factors II, V, VIII, IX, X, and XI and contact factors that do not influence bleeding (factor XII, prekallikrein, and high molecular weight kininogen) Does not detect most fibrinogen disorders Abnormalities need further investigation by specific factor assays, commonly to assess factors VIII, IX, XI, and XII, recognizing that factor XII deficiency is far more common than hemophilia or factor XI deficiency The test is prolonged in persons with Factor V-Short due to their increased plasma TFPI False positives due to lupus anticoagulants are common but are rarely associated with bleeding, unless there is an accompanying factor II deficiency If a bleeding disorder is suspected, factor assays should be performed to rule out a factor deficiency, regardless of any 1:1 mixing study findings
Clottable (Clauss) fibrinogen
Assesses fibrinogen function using a reagent that contains high concentrations of thrombin, which makes the test less susceptible to interference from heparin and direct thrombin inhibitors than the thrombin time Fibrinogen is reduced in hypo-, dys-, and afibrinogenemia, which can be distinguished by comparing the results for clottable fibrinogen, fibrinogen antigen, and the thrombin time We have found it useful to discuss with the patient about how many sample draws and visits are typically needed to complete tests for bleeding disorders (usually 2-3). We also discuss that no cause may be found, because mucocutaneous bleeding problems of undetermined cause are quite common.
14 If a person with significant bleeding problems has nondiagnostic findings, we consider the diagnoses that may have been overlooked and should be excluded. A thrombin time and a Clauss (clottable) fibrinogen determination should be included in initial investigations ( Figure 1 ) to ensure that fibrinogen disorders are adequately detected (Table 1) . 1, 2, 13 If the findings suggest a fibrinogen disorder, we then evaluate fibrinogen antigen levels and perform a Reptilase time to help distinguish between hypo-, dys-, and afibrinogenemia. 13 As dysfibrinogenemias are autosomal dominant, family studies often uncover additional cases, sometimes with minimal bleeding symptoms.
| Coagulation screening tests for the initial workup of a bleeding disorder
Tests Technical and diagnostic considerations
Factor XIII assays Assesses for factor XIII deficiency which is a rare bleeding disorder. Acquired causes account for about 10% of all cases Clot solubility assays only assess for severe deficiency and should not be performed when the fibrinogen level is reduced Factor XIII antigen and activity assays have the advantage of being able to detect less severe deficiencies than clot solubility assays. However, some factor XIII activity assays give false readings when factor XIII levels are below <15% of normal Deficiency of the enzymatic (A) subunit is the most common cause of severe congenital factor XIII deficiency. B subunit deficiencies cause less severe reductions in factor XIII activity than A subunit deficiencies Severe acquired factor XIII deficiency can be associated with accelerated factor XIII clearance (similar loss of activity and antigen) and/or neutralization of factor XIII activity (higher levels of antigen than activity, which may not be evident until treatment is started) α 2 antiplasmin function assays Assays of α 2 antiplasmin are helpful to assess a rare, severe congenital bleeding disorder that is more prevalent with consanguinity Markedly reduced activity (eg, <0.25 U/mL) does not exclude a complete deficiency as the assays lack validation with known severe deficient plasma because such samples are quite rare Mild deficiencies (eg, 50% reduction) are seen in carriers of α 2 antiplasmin deficiency who are typically asymptomatic α 2 antiplasmin levels are also reduced in severe PAI-1 deficiency, due to increased fibrinolysis Acquired α 2 antiplasmin deficiency (approximate levels: 0.30-0.79 U/mL) is common amongst acutely ill patients, reflecting consumption due to increased fibrinolysis PAI-1 antigen and activity assays PAI-1 antigen is useful to assess for severe PAI-1 deficiency (a rare, autosomal recessive bleeding disorder) Current PAI-1 activity assays lack a measurable lower limit and thus cannot be used to diagnose PAI-1 deficiency (Tables 1 and 2 ). Interestingly, valproic acid therapy is one of the more common causes of an isolated, prolonged thrombin time among individuals tested for bleeding disorders. 1,2 Drug effects need consideration when bleeding disorder investigations are requested after anticoagulation therapy is started (eg, to prevent stroke from atrial fibrillation) to further assess risks/benefits because of prior bleeding symptoms that had not been investigated (eg, menorrhagia, abnormal bruising, or excessive bleeding with surgical/dental and other challenges). If a physician orders bleeding disorder investigations on a patient taking a direct thrombin or factor Xa inhibitor, they should ask the patient to take their morning dose of anticoagulation after the investigations are drawn to limit drug interference. VWF:GPIbM reduces discrepancies as it has a lower coefficient of variation, detects lower levels of VWF, and is more sensitive to defects in VWF function. 5 As age, ABO blood group, exercise, stress, illness, pregnancy, and oral contraception influence VWF levels (see Table 1 ), repeat testing is often reasonable when VWF levels are mildly reduced or close to the lower limit of the reference range.
| Screening for defects in primary hemostasis when testing for a bleeding disorder
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As VWF levels increase by approximately 10% per decade of life,
21
caution is warranted when interpreting low VWF levels in children.
We have seen many individuals diagnosed with VWD at a young age . 23 The drug history should be carefully reviewed to determine whether the patient is taking any prescribed or over-the-counter medications that inhibit platelet function or cause bleeding.
1,10
We recommend an assessment of platelet function by LTA, ideally in the first step of bleeding disorder investigations, because platelet function disorders that impair LTA with ≥2 agonists are diagnosed at least as often as VWD when both conditions are evaluated. 1,2 Occasionally, a patient will have more than 1 common bleeding problem. LTA (performed according to recommended guidelines 10, 15 ) has good diagnostic performance, and it is essential and useful to diagnose rare bleeding disorders, such as Glanzmann thrombasthenia (GT) and Bernard-Soulier syndrome (BSS), and the more common platelet function disorders that impair aggregation responses to multiple agonists (which include autosomal dominant defects in transcription factors, such as RUNX1). 9, 12, 26, 27 LTA is also useful for the evaluation of acquired platelet function disorders.
Some laboratories perform LTA without adjusting the platelet count of platelet-rich plasma (PRP). 15 Our prospective, noninferiority study showed that PRP adjusted to 250 × 10 9 platelets/L is actually superior to native PRP for detecting reduced maximal aggregation (MA) with multiple agonists from a bleeding disorder, 9 an issue that other studies have not addressed. The use of adjusted PRP for LTA also reduces the need to draw larger volume blood samples, which is helpful for testing children. Compared to native PRP samples, adjusted PRP samples have similar responses to most agonists but lower MA responses to epinephrine and adenosine diphosphate 9 ;
laboratories should determine their own sample-type-specific ref-
erence interval for LTA, as recommended. 15 An evaluation of platelet granule secretion has been recommended for the routine evaluation of platelet function disorders 23 ;
however, there are uncertainties about the usefulness and reliability of secretion assays as diagnostic tests 4,28 which a minority of diagnostic laboratories perform. Nonetheless, defects in ATP release can be quite striking in some platelet disorders (illustrated in Reference 27). We now limit assessments of dense granule ATP release to the phenotyping of cases and families with other diagnostic platelet function abnormalities, such as impaired MA with ≥2 agonists 9, 12 and/or dense granule deficiency by whole mount EM. 4, 7, 27 When LTA is performed (with or without an assessment of dense granule release), abnormal findings need careful interpretation to determine whether the pattern could reflect congenital or acquired GT, BSS, an aspirin-like defect, a P2Y12 defect, or a gainof-function defect such as type 2B VWD or platelet-type VWD.
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Most patients with impaired MA with multiple agonists do not fit any of these patterns, 9, 12 and known causes include defects in signaling or secretion from a variety of causes (eg, dense granule deficiency or a platelet disorder with hereditary predisposition to myelodysplasia/leukemia from a RUNX1 mutation, among many others). 23, 26, 27 When platelet aggregometry findings are abnormal, the appropriate follow-up testing depends on the specific findings . 23 MA is the most useful parameter for LTA interpretation, 9,12 which should be consistent with guidelines recommendations. 7, 10 We test for platelet dense granule deficiency as a first or second step investigation for bleeding problems for several reasons. First, dense granule deficiency is almost as common as VWD. Second, confirmed platelet dense granule deficiency by whole mount EM is strongly predictive of a bleeding disorder, 29 unlike impaired dense granule ATP release. 4 Third, LTA and ATP release assays do not have sufficient sensitivity to screen for dense granule deficiency. 4, 29 Among diagnostic laboratories that test for platelet dense granule deficiency, most use the whole mount EM method. 3, 7, 11 While this EM test is relatively simple to perform, it does require an electron microscope and experienced technical staff to determine the average number of dense granules per platelet, based on an assessment of ≥30 platelets 11, 29 ). Proficiency testing challenges have shown good agreement between laboratories that perform whole mount EM, including their opinions on which structures should be counted as dense granules and which samples show normal or reduced dense granule numbers. 7, 11 The method has an acceptable coefficient of variation and while severe deficiencies in dense granules are typically evident on each sample, and borderline reductions in platelet dense granule counts are often not confirmed. 29 We recommend reassessment with a new sample if the first sample has a reduced platelet dense granule count. 29 While children and adults have similar numbers of dense granules in their platelets, 29 we recommend repeat testing at an older age when a child has a confirmed, reduced platelet dense granule count. Decisions on which coagulation factors to assess should be based on which tests show abnormalities, which abnormalities are most common, and to determine whether one or multiple factors are deficient (eg, low factor VIII suggestive of VWD or hemophilia A) ( Table 2) . We do not recommend using 1:1 mixing studies for bleeding disorder investigations as the findings could be misleading if there is mild deficiency and because quality-controlled assays for factor deficiencies are the most appropriate test for investigating an abnormal PT/INR and/or APTT in a person with a suspected bleeding disorder.
| Secondary and confirmatory investigations for bleeding disorders, including tests of factor XIII and fibrinolysis
When multiple coagulation factors are deficient, the cause is often an acquired disorder, although there are exceptions (eg, combined factor V and factor VIII deficiency) ( 
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If all coagulation factor levels are normal, drug effects should be considered along with the possibility of Factor V-Short (FV-Short).
31
FV-Short is an autosomal dominant bleeding disorder, due to a factor V gene mutation that truncates factor V while preserving factor V procoagulant activity. 31 FV-Short has an altered affinity for tissue factor pathway inhibitor (TFPI) that increases plasma TFPI levels, resulting in a prolonged PT/INR and APTT. 31 Research investigations are required to diagnose FV-Short.
An evaluation for factor XIII deficiency and fibrinolytic defects should be considered when the first stage investigations are normal and the type of bleeding (eg, intracranial hemorrhage, hematomas, delayed bleeding after challenges) warrants further testing for a defect in clot stabilization or fibrinolysis. While factor XIII deficiency, α 2 plasmin inhibitor deficiency, and plasminogen activator inhibitor-1 deficiency (PAI-1) are autosomal recessive (and hence rare), Quebec platelet disorder (QPD) is autosomal dominant. We recommend genetic testing for the QPD duplication mutation as the best method to diagnose or exclude QPD 32 ; this disorder manifests with delayedonset bleeding from a unique platelet-dependent, gain-of-function defect in fibrinolysis, without systemic fibrinolysis, that is caused by a duplication mutation of a 78 kb region on chromosome 10 that includes PLAU (the urokinase plasminogen activator, uPA, and gene).
QPD causes marked overexpression of uPA transcripts in megakaryocytes through unknown mechanisms. [32] [33] [34] In parts of Canada, the prevalence of QPD exceeds that of type 2B VWD and additional cases have been diagnosed in other regions, including the United States. Thromboelastography is insensitive to the fibrinolytic defect of QPD.
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It is important to consider that some bleeding disorders cause secondary abnormalities in other tests. For example, the increased fibrinolysis in severe PAI-1 deficiency reduces α 2 antiplasmin levels. 35 Acute illnesses can reduce the levels of factor XIII and α 2 plasmin inhibitor, although not as severely as congenital deficiencies. 1, 36 When testing children, it is important to consider age-related changes in hemostatic proteins as very few clinical laboratories have established age-specific reference intervals for children. 37 Genetic investigations have provided helpful insights on the causes of many bleeding disorders, including hemophilia, VWD, and platelet function disorders. 17, 18, 21, 25 While genetic testing is infrequently performed for diagnosing platelet disorders, it is warranted when the history suggests QPD and when the history and laboratory findings suggest the cause is an autosomal dominant platelet function disorder associated with hereditary predisposition to acute leukemia and myelodysplasia (eg, RUNX1 haploinsufficiency).
27,32
| CON CLUS IONS
Strategies for investigating bleeding disorders help guide stepwise, rational testing for both common and rare, inherited and acquired causes of bleeding.
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